A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma
Metastatic Cancer|Solid Tumor|Advanced Cancer|NonHodgkin Lymphoma
DRUG: Evorpacept (ALX148)|DRUG: Pembrolizumab|DRUG: Trastuzumab|DRUG: Rituximab|DRUG: Ramucirumab + Paclitaxel|DRUG: 5-FU + Cisplatin
Dose-limiting toxicities (Number of participants with a DLT), Number of participants with a DLT, Up to 28 days
This phase 1 clinical study (AT148001) is an open-label, multi-center, multiple-dose, dose-escalation, safety, PK, and PD study of evorpacept (ALX148). The phase 1 protocol will have 2 parts: a single agent dose escalation phase (Part 1) and a combination therapy phase (Part 2). Part 2 will include an initial dose escalation portion followed by a dose expansion portion. Approximately 184 adult patients are expected to be enrolled in the study.